Combined Thrombogenic Effects of Vessel Injury, Pregnancy and Procoagulant Immune Globulin Administration in Mice
Posted by Adam Awdish on
Innovative Grade US Origin Mouse C57BL6 Plasma and Pooled Human Plasma (Blood Derived) from Innovative Research was used in the following study:
Yanqun Xu, Yideng Liang, Leonid Parunov, Daryl Despres, Michael Eckhaus, Dorothy Scott, Mikhail Ovanesov & Evi B. Struble
Thrombosis Journal
November 7, 2020
Normal pregnancies create hypercoagulable conditions within the body to naturally lower the risk of bleeding during birth. However, the changes observed in the hemostatic system also put pregnant women at risk of various thrombotic events (TEs), such as deep venous thrombosis (DVT), pulmonary embolism, cerebral vein thrombosis, myocardial infarction, and stroke. As an example, compared to non-pregnant women of the same age and health status, pregnant women are susceptible to up to a 10-fold increased risk of developing DVT.
Immune globulin (IG) products are commonly used in pregnancies to prevent recurring complications, repeated loss of pregnancies, and other pregnancy-related diseases and conditions, however US and European regulators announced in 2010 that a link had been identified between elevated activated Factor XI (FXIa) levels in IG products and an increased risk of thrombosis. In fact, early plasma-derived FXI treatments caused FXI-deficient patients to suffer severe TEs. This, combined with in vitro and in vivo observations of procoagulant effects resulting from the selective depletion on FXIa, brought upon changes in how IG products were manufactured that resulted in an improved safety profile.
Currently, there have not been any studies that focus specifically on the association between pregnancy and thrombosis following IG therapy, and in-depth studies in animals have not been reported. Further, most in vivo animal research on coagulation and hemostasis are performed in mice, and there is currently little to no research focusing on how accurately pregnant mice replicate the hypercoagulable state of human pregnancy. The goal of this study was to compare the thrombogenic risks associated with non-procoagulant IG infusions both with and without added FXIa. Findings suggest that pregnancy does not result in significant differences in femoral vessel occlusion in mice, however FXIa treatment did result in faster blood velocity reduction. Further, they unexpectedly discovered that FXIa activity continues in circulation despite the presence of proteins that typically render it inactive.
Related products available from Innovative Research also include:
Innovative Grade US Origin Mouse C57BL6 Whole Blood